The Board of Directors of Guerbet, convened on January 28, 2026, upon the recommendation of the Nominations and Compensation Committee, decided to appoint Karim Boussebaa as the CEO of the group. The appointment will be effective from February 2, 2026. Karim Boussebaa is a graduate from the National School of Advanced Sciences and Technologies and holds an MBA from Westminster College (Salt Lake City, USA). He has over 25 years of international experience in the health and medical technology sectors, having previously held leadership positions in leading groups in the fields of medical imaging and medical devices.
Previous Interim CEO
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Jérôme Estampes, who served as the interim CEO, will resume his role as Director of Group Financial Affairs and SVP of Business Development and Licenses starting February 2, 2026.
Related
SectorIndustrie Pharmaceutique et Biotechnologie›Industrie Pharmaceutique
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
